# Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

> **NCT00534638** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 34412 (actual)

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **BIOLOGICAL:** Cervarix
- **BIOLOGICAL:** Engerix-B

## Key facts

- **NCT ID:** NCT00534638
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-04
- **Primary completion:** 2014-12-17
- **Final completion:** 2014-12-17
- **Target enrollment:** 34412 (ACTUAL)
- **Last updated:** 2019-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00534638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00534638, "Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00534638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*